

EUROPEAN CV FORMAT



PERSONAL INFORMATION

Name	CAIROLI ROBERTO
Address	MONZA (MI), ITALIA
Telephone	+39-02-6444 2668 (hospital)
Fax	+39-02-6444 3650 (hospital)
E-mail	roberto.cairol@ospedaleniguarda.it

Nationality	ITALIAN
-------------	---------

Date of birth	17. 10. 1958
---------------	--------------

WORK EXPERIENCE

• Date (from – to)	October 2014- present
Employer's name and address	Niguarda Hospital, Piazza Ospedale Maggiore 3, 20162, Milano (I)
• Sector	Haematology division
• Employment type	Medical Doctor
• Main activities and responsibilities	Director
• Date (from – to)	April 2011- September 2014
• Employer's name and address	Valduce Hospital, Via Dante 11, Como (I)
• Sector	Division of Internal Medicine and Section of Hematology
• Employment type	Medical Doctor
• Main activities and responsibilities	Director
• Date (from – to)	March 2007- March 2011
• Employer's name and address	Niguarda Hospital, Piazza Ospedale Maggiore 3, 20162, Milano (I)
• Sector	Department of Transfusion Medicine and Hematology (DMTE)
• Employment type	Medical Doctor
• Main activities and responsibilities	Director

• Date (from – to)	March 1988 – March 2007
• Employer's name and address	ASST Grande Ospedale Metropolitano Niguarda Hospital, P Ospedale Maggiore 3, 20162, Milano (I)
• Sector	Haematology division
• Employment type	Medical Doctor
• Main activities and responsibilities	Head of "Autologous Transplant of haematopoietic progenitors" Unit (1998 - 2007)
• Date (from – to)	Academic year 1999 – 2011
• Employer's name and address	Università degli Studi di Milano, Milano (I)
• Sector	Department of Medicine, School of specialization in genetics
• Employment type	Contracted Professor
• Main activities and responsibilities	Face-to-face lessons, organization of seminars / lab training

• Date (from – to)	Academic year 2014 – present
• Employer's name and address	Università degli Studi di Milano, Milano (I)
• Sector	Department of Medicine, School of specialization in hematology
• Employment type	Contracted Professor
• Main activities and responsibilities	Face-to-face lessons, organization of seminars

EDUCATION AND TRAINING

• Date	23 / 03 /1984
• Name and type of educational or training institute	Università degli Studi di Milano
• Title of qualification awarded	Degree in Medicine and Surgery
• Result	110/110 with honours
• Date	30 / 09 / 1988
• Name and type of educational or training institute	Università degli Studi di Pavia
• Title of qualification awarded	Specialization in General Haematology (Clinical and laboratory)
• Date	03 / 11 /1994

• Name and type of educational or training institute	Università degli Studi di Milano
• Title of qualification awarded	Specialization in Chemotherapy
• Name and type of educational or training institute	Ministero della Università e della Ricerca
• Title of qualification awarded	Abilitazione Scientifica Nazionale: Associate Professor Settore concorsuale 06/D3, Ematologia. November 2020- November 2029.
ONLINE COURSES	<p>1) 7.00x: Introduction to Biology The Massachusetts Institute of Technology (USA) ; Issued September 11, 2014 https://verify.edx.org/cert/abbc3b5886ec4f289ff8ba4eb384b593</p> <p>2) IO101x: The Immune System: New Developments in Research Osaka University (Japan); Issued September 01, 2015 https://verify.edx.org/cert/81592a08a62a4786be5c224e2c4b324e</p> <p>3) BIOC372.1x: Fundamentals of Immunology, Part 1 Rice University (USA) Issued December 7, 2015 https://courses.edx.org/certificates/909e3f67a8d0484b9e82b51db8980265</p> <p>4) BIOC372.2x: Fundamentals of Immunology, Part 2 Rice University (USA) Issued March 16, 2016 https://courses.edx.org/certificates/1d3003b5af59403e833da16481eee0b2</p> <p>5) UseGen.1x: Useful Genetics - Part 1 The University of British Columbia (CANADA) Issued January 8, 2017 https://courses.edx.org/certificates/c67dcfbea80842228dd2b3c66dcf87d</p> <p>6) BIOC300.2x: DNA: Biology's Genetic Code RICE University (USA); Issued November 18, 2017 https://courses.edx.org/certificates/0cc91c4c3b1e499e8612cfb6ce698df6</p> <p>7) SNUM1409.000300.1x: DNA and Atoms: The Secret of Life Seoul National University (South Korea); Issued February 1, 2018 https://courses.edx.org/certificates/5d71daa3e58e4417a507618808a00198</p> <p>8) HPH-101X: Lifestyle Medicine Core Principles Doane University (USA); Issued October 4, 2018 https://courses.edx.org/certificates/fc32d3a17c8241e4a9d5166d47be1aca</p> <p>9) The Chemistry of Life Kyoto University (Japan); Issued February 1, 2020 https://courses.edx.org/certificates/9a58caae0b814a04b6e60a3c50a68e4d</p>

	<p>10) Cell Biology Transport The Massachusetts Institute of Technology (USA) Issued December 3, 2020 https://courses.edx.org/certificates/89c9b248ca3b4ce09c8fb8f8229c1851</p> <p>11) Biochimica FedericaX-Napoli (Italia) Issued January 4, 2021 https://courses.edx.org/certificates/dfd53a97d7d3428692405356f81c7d20</p> <p>12) Cell Biology: Signaling The Massachusetts Institute of Technology (USA) Issued:</p>
--	---

MOTHER TONGUE	ITALIAN
---------------	----------------

OTHER LANGUAGES

	ENGLISH
• Reading skills	GOOD
• Writing skills	GOOD
• Verbal skills	GOOD (C1)
	FRENCH
• Reading skills	EXCELLENT
• Writing skills	GOOD
• Verbal skills	GOOD

**PERSONAL SKILLS AND
COMPETENCES**

Haematology Department: Clinical Ward, Day Hospital, Bone Marrow Transplant Centre

Diagnosis and treatments of Acute Leukemias, NHL, AA, MM, MPD, MDS and other hematologic malignancies. Supportive care. Benign hematology. Morphology: reading and results interpretation of bone marrow and peripheral blood smears.

Inter-departmental consultancy and departmental duty doctor activities.

Bone marrow harvesting under general anaesthesia for bone marrow transplants. Selection and clinical management (care in protected environment and out-patients follow-up) of patients undergoing autologous and allogeneic stem cells transplants from related and unrelated donors and with myeloablative or non-myeloablative conditioning. Management of bone marrow / circulating haematopoietic progenitor donors.

Since 1995, I have implemented the clinical work of “circulating haematopoietic progenitor transplants” at the Haematology Department of Niguarda Hospital in Milan, covering the following roles:

- *since January 1998, “1st level director with responsibility for teaching and/or head of research in the sector of autologous transplant of haematopoietic precursors”;*
- *since October 1999, “Management of activities referring to autologous transplant of haematopoietic precursors and coordination within the Transfusion Medicine Service in collection and manipulation of stem cells for clinical use and organization of laboratory work”;*
- *since January 2004, “Assignment of High specialization in the field of intensive chemotherapy and stem cells transplantation”.*

Cell therapy laboratory

Use of cell separators for collecting haematopoietic progenitors mobilized in peripheral blood. Ex-vivo manipulation of the bone marrow and haematopoietic progenitors for auto-transplant. Techniques for removing incompatible ABO RBC for allogeneic transplant. Positive selection techniques of circulating and/or bone marrow cells (haematopoietic progenitors, malignant cells) for clinical and in-vitro use.

Since 1995, following some experience in Italy and abroad (August 1990: at the Fred Hutchinson Cancer Research Center, bone marrow transplantation clinical ward, Seattle, WA, USA; October 1994: at the University of S.Diego, Stem cells laboratories, San Diego, CA, USA) I set up and/or completed, in teams of colleagues from the laboratory, haematology and transfusion medicine all the main procedures (mobilization, enumeration, collection, minimal manipulation, purification, cryoconservation, storage and quality control of circulating haematopoietic progenitors cells) necessary for starting up “Peripheral Blood Stem Cell Transplantation” activities.

Consultancy activities

Since 2001, I have carried out general haematology consultancy activities at the S. Anna Hospital in Como, as set out in the relevant agreement. From 2011 to 2012 I have carried out research consultancy activities at the Niguarda Hospital in Milan.

Research activities

Since 1997, when I started working with the Department of Biology and Genetics (University of Milan) - I have contributed to the planning, design and creation of research projects in the field of hematologic malignant diseases. Main areas of interest: AML, CML, Translational medicine, Immune Thrombocytopenia.

My research interest has been focused on cancer molecular genetics, and particularly on the receptor protein-tyrosine kinases driving oncogenic signal networks involved in the development of leukemia.

1) During the years (1997-1999) in a joint program with University of Milan, my scientific research was mainly focused on the oncogenic kinase signalling in the development of Acute Myeloid Leukemia (AML). A relevant step of my career advancement has been **the first evidence for the involvement of KIT gene in the human AML and particularly the peculiar association with core binding factor deranged-related neoplasms** obtained by our group. Our following publications on the diagnostic/prognostic value of KIT mutations in AML have been recognized in the definition of molecular genetic alterations affecting clinical outcome of AML patients in specific cytogenetic group and included in: S.H. Swerdlow, et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues (revised 4th Edition, International Agency for Research on Cancer, Lyon 2017 at page 146, Reference n°523A) and the inclusion in the NCCN clinical practice guidelines in oncology (Acute Myeloid Leukemia versions 3.2019, Ref. 54 and the updated online version 3.2020).

2) On the side of the clinical research, in the context of the KIT mutated alleles in core binding factor leukemias, **I am currently coordinating an AIFA approved multicentric phase II trial (EudraCT number: 2017-002094-18)** in a joint collaboration with the Regional Hematological Network (REL-Rete Ematologica Lombarda). The aim of the project has been to interrogate the clinical relevance of specific mutations in homogeneously midostaurin treated clinical cohort.

3) The first hint that A-to-I RNA editing has fundamental implications in leukemic disorders derives from our detection of altered editing events in the protein tyrosine phosphatase, non-receptor type 6 (PTPN6) transcript of patients affected by AML. These observations opened up a peculiar mechanism, cited in several high impact reviews, involving post-transcriptional RNA editing, causing loss-of-function mutations in leukaemic patients (DOI: 10.1158/0008-5472.CAN-17-0520; 10.1038/leu.2017.134; 10.1038/35098584).

4) More recently, I turned my efforts towards the establishment and

coordination of an interdisciplinary research network aimed to approach integrated genome-wide analysis of gene expression programs in hematological malignancies. The very first results of these relationships are represented by several published papers, in particular we support a model in which **core-binding factor (CBF) genetic abnormalities can lead to the overexpression of (wild type or mutated) KIT receptor** by direct down-regulation of CBF-regulated microRNA (MIR-221/222). This mechanism would explain, at least in part, the concerted contribution of class I and class II mutations to the pathogenesis of CBF-leukemia.

5) Another exciting area of research, that stems from our research plans on hematological malignancies, examines the gene expression programs involved in the early development of cancer stem cell.

Recently, we showed an **increase of WNT10B ligand expression and release within the microenvironment and described a new recurrent rearrangement in the large majority of AML patients**, indicating its possible autocrine/paracrine involvement in the bone marrow microenvironment, and suggesting that the regenerative WNT signaling is a stem cell-associated function altered in AML AC133^{bright} cell fraction.

Research Grants

Years 2004-2017

- ***Ruolo delle mutazioni attivanti KIT nelle Leucemie Mieloidi Acute; screening mutazionale, implicazioni prognostiche e sensibilità al trattamento in vivo con Imatinib Mesilato.***

Ente Finanziatore: Regione Lombardia, Direzione Generale Sanita'.

Bando Piano Regionale Sangue 2004. Durata 36 mesi.

Ruolo ricoperto: Responsabile Scientifico di Progetto.

- ***Caratterizzazione delle modulazioni trascrizionali e post-trascrizionali in frazioni di cellule staminali ematopoietiche di soggetti normali ed in pazienti affetti da Leucemia Mieloide Acuta.***

Durata 36 mesi. Ruolo ricoperto: Corresponsabile Scientifico.

Ente Finanziatore: Regione Lombardia, Direzione Generale Sanita'.

Bando Piano Regionale Sangue. Anno 2006. Trasferimento quota a saldo del progetto approvato con DDG n. 7917 su nuova linea di ricerca.

- ***Impiego di rHuEpo nella fase pre trapianto autologo di cellule staminali emopoietiche, in pazienti affetti da mieloma multiplo e linfoma non Hodgkin, per ridurre il fabbisogno trasfusionale dopo condizionamento mieloablativo. Uno studio aperto, monocentrico di fase III.***

Ente Finanziatore: Regione Lombardia, Direzione Generale Sanita'.

Bando Piano Regionale Sangue 2007. Durata: 24 mesi.

Ruolo ricoperto: Responsabile Scientifico di Progetto.

- ***Trasfusioni sicure integrate: processi e sistemi evoluti per la***

gestione trasfusionale.

Ente Finanziatore: Regione Lombardia, Direzione Generale Sanita'.
Bando Piano Regionale Sangue 2007. Durata: 24 mesi.
Ruolo ricoperto: Responsabile Scientifico di U.O.

- **Fotochemioterapia Extracorporea (ECP) nella profilassi della GVHD in pazienti sottoposti a trapianto allogenico di cellule staminali con condizionamento ridotto. Uno studio multicentrico di fase II.**

Ente Finanziatore: Regione Lombardia, Direzione Generale Sanità.
Bando Piano Regionale Sangue 2008.
Durata: 24 mesi. Ruolo ricoperto: Responsabile Scientifico di Progetto.

- **Genome wide association study to identify novel risk loci for severe obesity.**

Ente Finanziatore: Ministero della Salute. Anno 2009.
Durata: 24 mesi. Ruolo ricoperto: Responsabile Scientifico di U.O.

- **Studio dell'appropriatezza dell'utilizzo degli emocomponenti in riferimento alle linee guida regionali: sperimentazione di un sistema di benchmarking trasfusionale e valutazione degli interventi correttivi.**

Ente Finanziatore: Regione Lombardia, Direzione Generale Sanita'.
Bando Piano Regionale Sangue 2009. Durata: 24 mesi.
Ruolo ricoperto: Responsabile Scientifico di U.O.

- **Tipizzazione HLA classe II alta risoluzione mediante sequenziamento diretto su 100 donatori iscritti a MI05.**

Ente Finanziatore: Associazione Donatori Midollo Osseo (ADMO). Anno 2010. Durata: 12 mesi.
Ruolo ricoperto: Responsabile Scientifico di Progetto.

- **Multidimensional classification of lymphohematopoietic malignancies. Sottoprogetto: "Profili di espressione genica nella leucemia mieloide acuta: correlazione con indicatori prognostici e terapeutici"**

Ente finanziatore: Ministero della Salute, Programma Integrato Oncologia 2008-2011. RO4/2007 Durata 36 mesi.
Ruolo ricoperto: Corresponsabile scientifico.

- **Bando 2015 per la valorizzazione della ricerca biomedica nell'ambito della medicina traslazionale e personalizzata e della ricerca clinica spontanea (FRRB 2015). Progetto: Genomic Profiling of rare hematologic malignancies, development of personalized medicine strategies, and their implementation into Rete matologica Lombarda (REL) clinical network**

Ente finanziatore: Regione Lombardia. Durata 36 mesi.
Ruolo ricoperto: Responsabile Scientifico di U.O.

Scientific Societies

Member and Regional Delegate of SIE (Società Italiana di Ematologia); Member, Board of REL (Rete Ematologica Lombarda); Member of SIES (Società Italiana di Ematologia Sperimentale), GITMO (Gruppo Italiano Trapianti Midollo Osseo), EBMT (European Bone Marrow Transplantation), EHA (European Hematology Association); Member of San Raffaele Hospital ethics committee.

“I conducted clinical research according to GCP and I authorize the use of my personal data according to D.Lgs. N° 196/2003”.

Milano, 4 Gennaio 2021

Roberto CAIROLI

Roberto Cairoli



Indicatori Bibliografici

Source: Web of Science

Total Publications: 244

H-index: 24

Citations (total): 2570, without self citations: 2498.

- Cattaneo C, Daffini R, Pagani C, Salvetti M, Mancini V, Borlenghi E, D'Adda M, Oberti M, Pains A, De Ciuceis C, Barbullushi K, Cancelli V, Belotti A, Re A, Motta M, Peli A, Bianchetti N, Anastasia A, Dalceglio D, Roccaro AM, Tucci A, Cairoli R, Muiesan ML, Rossi G. CLINICAL CHARACTERISTICS AND RISK FACTORS FOR MORTALITY IN HEMATOLOGIC PATIENTS AFFECTED BY COVID-19. CANCER, 2020
- Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli, F.g, Angelucci, E.h, Krampera, M.i, Cairoli R et al (ITA-HEMA-COV Investigators).Clinical characteristics and risk factors associated with COVID-19 severity in patients with hematological malignancies in Italy: a multicentre, cohort study. THE LANCET HAEMATOLOGY, 2020
- Anna Maria Frustaci, Alessandra Tedeschi, Marina Deodato, Giulia Zamprogna, Cairoli R, Marco Montillo. Duvelisib for the treatment of chronic lymphocytic leukemia. EXPERT OPINION ON PHARMACOTHERAPY, 2020
- Cairoli R, Ferrara F, Girmenia C, Luppi L, Pea F, Specchia G Venditti A. Management of patients with acute myeloid leukemia undergoing therapy with midostaurin: a focus on antifungal prophylaxis. HEMATOLOGICAL ONCOLOGY, 2020
- Chiaretti S; Messina M; Della Starza I; Piciocchi A; Cafforio L; Cavalli M; Taherinasab A; Ansuinelli M; Elia L; Albertini Petroni G; La Starza R; Canichella M; Lauretti A; Puzzolo MC; Pierini V; Santoro A; Spinelli O; Apicella V; Capria S; Di Raimondo F; De Fabritiis P; Cristina Papayannidis; Anna Candoni; Cairoli R; Cerrano M; Fracchiolla N; Mattei D; Cattaneo C; Vitale A; Crea E; Fazi P; Mecucci M; Rambaldi A; Guarini A; Bassan R; R Foà. Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913. HAEMATOLOGICA, 2020
- Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih, HR, Annibaldi O, Wattad M, Lubbert M, Brandts C, Hanel M, Rollig C, Schmitz N, Lin H, Frairia C, Fozza C, Maria D'Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Teresa Voso M, Ehninger G, Schlenk RF, Lo-Coco F. Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. LEUKEMIA, 2020.
- Cento V, Alteri C, Mancini V, Gatti M, Lepera V, Mazza E, Moioli MC, Merli, M.g, Colombo, J.h,

Orcese, C.A.g, Bielli, A.e, Torri, S.a, Gasparini, L.E.d, Vismara, C.e, De Gasperi, A.f, Brioschi, P.d, Puoti, M.g, Cairoli R, Lombardi G, Perno CF. Quantification of 1,3-β-D-Glucan by Wako β-Glucan Assay for rapid exclusion of invasive fungal infections in critical patients: a diagnostic test accuracy study. MYCOSES, 2020

- Zilioli V, Muzi C, Minga P, Codega P, Crucitti L, Meli E, Esposito A, Panico C, Rusconi C, Cairoli R. Safety and efficacy of NEPA and dexamethasone in Hodgkin's lymphoma patients: a single-center real-life experience. INTERNATIONAL JOURNAL OF HEMATOLOGIC ONCOLOGY, 2020

- Frustaci AM, Zamprogna G, Deodato M, Cairoli R, Montillo M, Tedeschi A. The management of chronic lymphoproliferative disorders at the time of SARS-Covid2 pandemic: weathering the storm. LEUKEMIA & LYMPHOMA, 2020

- Anna M Frustaci, Alessandra Tedeschi, Marina Deodato, Giulia Zamprogna, Cairoli R, Marco Montillo. Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia. FUTURE ONCOLOGY, 2020

- Adriano Venditti, Alfonso Piciocchi, Anna Candoni, Lorella Melillo, Valeria Calafiore, **Cairoli R**, PAOLO DE FABRITIIS, Gabriella Storti, Prassede Salutari, FRANCESCO LANZA, Giovanni Martinelli, Mario Luppi, Patrizio Mazza, Maria Paola Martelli, Antonio cuneo, Francesco Albano, Francesco fabbiano, Agostino Tafuri, Anna Chierichini, Alessia Tieghi, Nicola S Fracchiolla, Debora Capelli, Robin Foà, Caterina Alati, Edoardo la Sala, Paola fazi, Marco Vignetti, Luca Maurillo, Francesco Buccisano, Maria Ilaria Del Principe, Maria Irno-Consalvo, Tiziana Ottone, Serena lavorgna, Maria Teresa Voso, Francesco Lo Coco, William Arcese, Sergio Amadori (in stampa). GIMEMA AML1310 TRIAL OF RISK-ADAPTED, MRD-DIRECTED THERAPY FOR YOUNG ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA. BLOOD, 2019

- Alessandra Trojani, Ester Pungolino, Alessandra Dal Molin, Milena Lodola, Giuseppe Rossi, Mariella D'Adda³, Alessandra Perego⁴, Chiara Elena⁵, Mauro Turrini, Lorenza Borin, Cristina Bucelli, Simona Malato, Maria Cristina Carraro, Francesco Spina, Maria Luisa Latargia, Salvatore Artale, Pierangelo Spedini, Michela Anghileri, Barbara Di Camillo, Giacomo Baruzzo, Gabriella De Canal, Alessandra Iurlo, Enrica Morra, **Cairoli R**. Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment. PLOS ONE, 2019

- Deodato M, Frustaci AM, Zamprogna G, **Cairoli R**, Montillo M, Tedeschi A. (2019). Ibrutinib for the treatment of chronic lymphocytic leukemia. EXPERT REVIEW OF HEMATOLOGY, 2019

- Alfonso V, Iaccarino L, Ottone T, Cicconi L, Lavorgna S, Divona M, **Cairoli R**, Cristiano A, Ciardi C, Travaglini S, Falconi G, Hasan SK, Venditti A, Arcese W, Voso MT, Lo-Coco F. (2019). Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia. LEUKEMIA, ISSN: 0887-6924, 2019

- Anna M Frustaci, Alessandra Tedeschi, Marina Deodato, Giulia Zamprogna, **Cairoli R**, Marco Montillo. Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia. FUTURE ONCOLOGY, ISSN: 1479-6694, 2019

- Molteni A, Ravano E, Riva M, Nichelatti M, Bandiera L, Crucitti L, Truini M, **Cairoli R**. Prognostic impact of immunohistochemical p53 expression in bone marrow biopsy in higher risk MDS: A pilot study. MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, ISSN: 2035-3006, 2019

- Pungolino E, Rossi, G.b, De Canal, G.c, Trojani, A.a, D'adda, M.b, Perego, A.d, Orlandi, E.M.e, Lunghi, F.f, Turrini, M.g, Borin, L.h, Iurlo, A.i, Latargia, M.L.j, Carraro, M.C.k, Spina, F.l, Lodola, M.a,

Artale, S.m, Anghilieri, M.n, Spedini, P.o, Cantoni, S.a, Di Camillo, B.p, Morra, E.q, **Cairolì R.** Nilotinib induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-chronic myeloid leukemia. AMERICAN JOURNAL OF HEMATOLOGY, 2018

- Tiziana Lazzarotto, Angela Chiereghin, Antonio Piralla, Giulia Piccirilli, Alessia Girello, Giulia Campanini, Liliana Gabrielli, Cristina Costa, Arcangelo Prete, Francesca Bonifazi, Alessandro Busca, **Cairolì R**, Anna Amelia Colombo, Marco Zecca, Francesca Sidoti, Gabriele Bianco, Pierpaolo Paba, Carlo Federico Perno, Rossana Cavallo, Fausto Baldanti . CMV and EBV DNA Kinetics in Whole Blood and Plasma of Allogeneic Hematopoietic Stem Cell Transplant Recipients. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, ISSN: 1083-879, 2018

- Reda G, Riva M, Fattizzo B, Cassin R, Giannarelli D, Pennisi M, Freyrie A, **Cairolì R**, Molteni A, Cortelezzi A. (2018). Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia. SEMINARS IN HEMATOLOGY, vol. 55, p. 202-208, ISSN: 0037-1963, 2018

- Alessandra Trojani, Ester Pungolino, Alessandra Dal Molin, Milena Lodola, Gabriella De Canal, Giuseppe Rossi, Mariella D'Adda, Alessandra Perego, Ester Orlandi, Malato Simona, Mauro Turrini, Lorenza Borin, Alessandra Iurlo, Maria Luisa Latargia, Maria Cristina Carraro, Francesco Spina, Salvatore Artale, Michela Anghilieri, Francesco Lanza, Enrica Morra, **Cairolì R.** Genes and Pathways Dysregulated by Nilotinib Treatment in Bone Marrow CD34+/Lin- Cells of Patients with Chronic-Phase Chronic Myeloid Leukaemia. EUROPEAN MEDICAL JOURNAL. HEMATOLOGY, ISSN: 2053-6631, 2018

- Cereda AF, Moreo AM, Sormani P, De Chiara B, Casadei F, Zancanella M, Rusconi C, **Cairolì R**, Giannattasio C Impact of serial echocardiography in the management of primary cardiac lymphoma. J. S. Heart Association. Doi:10.1016/j.jsha.2017.08.001, 2018

- Cantoni S, Carpenedo M, Mazzucconi MG, De Stefano V, Carrai V, Ruggeri M, Specchia G, Vianelli N, Pane F, Consoli U, Artoni A, Zaja F, D'adda M, Visentin A, Ferrara F, Barcellini W, Caramazza D, Baldacci E, Rossi E, Ricco A, Ciminello A, Rodeghiero F, Nichelatti M, **Cairolì R.** Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers. Am J Hematol. Jan;93(1):58-64. doi: 10.1002/ajh.24935. PMID:28983953, 2018

- Borlenghi E, Pagani C, Zappasodi P, Bernardi M, Basilico C, Todisco E, Fracchiolla N, Mancini V, Turrini M, Da Vià M, Sala E, Cattaneo C, Petullà M, Serana F, Ferrario A, **Cairolì R**, Cortelezzi A, Santoro A, Castagnola C, Rossi G. Secondary acute myeloid leukemia in elderly patients: patient's fitness criteria and ELN prognostic stratification can be applied to guide treatment decision. An analysis of 280 patients by the network rete Ematologica Lombarda (REL). Am J Hematol. Feb;93(2):54-57. doi: 10.1002/ajh.24977. PMID:29164738, 2018

- Mazzucchelli M, Frustaci AM, Deodato M, **Cairolì R**, Tedeschi A. Waldenstrom's Macroglobulinemia: An Update. Mediterr J Hematol Infect Dis, Jan 1;10(1):e2018004. doi: 10.4084/MJHID.2018.004. Review. PMID:29326801, 2018

- Tedeschi A, Frustaci AM, Mazzucchelli M, **Cairolì R**, Montillo M. Is HBV prophylaxis required during CLL treatment with Ibrutinib? Leuk Lymphoma. 58(12):2966-2968. doi: 10.1080/10428194.2017.1317094. PMID: 28535112, 2017

- Grossi G, Viganò M, Facchetti F, Labanca S, Loglio A, Dodero A, Montefusco V, Corradini P, Cafro A, **Cairolì R**, Colombo M, Lampertico P. Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogeneic hematopoietic stem cell

transplantation for hematological malignancies: two case reports. *Haematologica*. Oct;102(10):423-426. doi: 10.3324/haematol.168609. PMID:28659333, 2017

- Fracchiolla NS, Todisco E, Bilancia A, Gandolfi S, Orofino N, Guidotti F, Mancini V, Marbello L, Assanelli A, Bernardi M, Santoro A, **Cairolì R**, Consonni D, Cortelezzi A. Clinical management of peripherally inserted central catheters compared to conventional central venous catheters in patients with hematological malignancies: A large multicenter study of the REL GROUP (Rete Ematologica Lombarda - Lombardy Hematologic Network, Italy). *Am J Hematol*. Dec;92(12):656-659. doi: 10.1002/ajh.24903. PMID:28891226, 2017
- Trojani A, Pungolino E, Rossi G, D'Adda M, Lodola M, Camillo BD, Perego A, Turrini M, Orlandi E, Borin L, Iurlo A, Malato S, Spina F, Latargia ML, Lanza F, Artale S, Anghilieri M, Carraro MC, Canal G, Morra E, **Cairolì R**. Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment. *Cancer Biomark*. Dec 12;21(1):41-53. doi: 10.3233/CBM-170209. PMID:29036785, 2017
- Frustaci AM, Tedeschi A, Deodato M, Mazzucchelli M, **Cairolì R**, Montillo M. Ibrutinib and its use in the treatment of chronic lymphocytic leukemia. *Future Oncol*. Dec 15. doi: 10.2217/fon-2017-0466. PMID:29243946, 2017
- Martina Pennisi, Clara Cesana, Micol Cittone, Laura Bandiera, Barbara Scarpati, Valentina Mancini, Silvia Soriani, Silvio Veronese, Mauro Truini, Silvano Rossini and **Roberto Cairolì**. A case of "mature" blastic plasmacytoid dendritic cell neoplasm extensively studied by immunophenotype and immunohistochemistry. *Case Rep Hematol* 4984951. doi: 10.1155/2017/4984951. PMID:28409040, 2017
- Clara Cesana, Barbara Scarpati, Bruno Brando, Linda Scampini, Giuseppa Liga, Catherine Klersy, Michele Chiericozzi, Vittorio Ruggero Zilioli, Chiara Rusconi, Michele Nichelatti, Stefano Fieschi, Massimo Torre, Angelo Vanzulli, **Roberto Cairolì**, Silvano Rossini. Flow cytometry analysis of lymphocyte subsets in bronchoalveolar lavage: comparison between lung non-hodgkin lymphomas and reactive diseases. *Comparative Clinical Pathology*; 26 (2): 447-454, 2016
- Molteni A, Riva M, Marbello L, Mancini V, **Cairolì R**. Clofarabine based chemotherapy as bridge to transplant in the setting of refractory or relapsed Acute Myeloid Leukemia, after at least one previous unsuccessful salvage treatment containing Fludarabine. A single institution experience. *Int. J of Hematology*; 105(6):769-776. doi: 10.1007/s12185-017-2198-0. PMID:28220349, 2017
- Paola Picardi, Anna Maria Frustaci, Maddalena Mazzucchelli, **Roberto Cairolì**, Alessandra Tedeschi and Marco Montillo. Monoclonal Antibodies in Chronic Lymphocytic Leukemia. *Lymphoma and Chronic Lymphocytic Leukemias*; 6 1–11 doi:10.4137/LCLL.S18491, 2016
- Francesca Lazzaroni, Luca Del Giacco, Daniele Biasci, Mauro Turrini, Laura Prosperì, Roberto Brusamolino, **Roberto Cairolì**, Alessandro Beghini. Intronless WNT10B-short variant underlies new recurrent allele-specific rearrangement in acute myeloid leukaemia. *Sci. Rep.* **6**, 37201; doi: 10.1038/srep37201, 2016
- Cantoni S, Carpenedo M, Nichelatti M, Sica L, Rossini S, Milella M, Popescu C, **Cairolì R**. Clinical relevance of anti-platelet antibodies and the hepatic clearance of platelets in patients with immune thrombocytopenia (ITP). *Blood* Oct 27;128(17):2183-2185. PMID:27601463, 2016
- Frustaci AM, Tedeschi A, Picardi P, Mazzucchelli M, **Cairolì R**, Montillo M. Ofatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association data. *Ther Adv Hematol*.

Aug;7(4):222-30. doi: 10.1177/2040620716648567. Epub 2016 May 21. Review. PMID: 2749371, 2016

- Platzbecker U, Avisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, **Cairolì R**, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. *J Clin Oncol*; 35(6): 605-612. Jul 11. pii: JCO671982. PMID: 27400939, 2017
- Frustaci AM, Montillo M, Picardi P, Mazzucchelli M, **Cairolì R**, Tedeschi A. Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future? *Expert Rev Hematol*. Jul;9(7):679-93. doi: 10.1080/17474086.2016.1191943. Epub 2016 Jun 8. PMID: 27253240, 2016
- Molteni A, Riva M, Borin L, Bernardi M, Pelizzari AM, Freyrie A, Della Porta M, Nichelatti M, Ravano E, Quaresmini G, Mariotti J, Caramazza D, Ubezio M, Guarco S, Gigli F, Greco R, **Cairolì R**, Morra E. The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the "Rete Ematologica Lombarda". *Leuk Res*. Mar;42:21-7. doi: 10.1016/j.leukres.2016.01.006. Epub 2016 Jan 18. PMID: 2685200, 2016
- Iaccarino L, Ottone T, Divona M, Cicconi L, **Cairolì R**, Voso MT, Lo-Coco F. Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia. *Br J Haematol*. 2016 Mar;172(6):909-13. doi: 10.1111/bjh.13910. Epub 2016 Jan 5. Erratum in: *Br J Haematol*. Jul;174(2):335. PMID: 26728337, 2016
- Bertani G, Santoleri L, Ferri U, Marengo P, Grillo G, Zucchetti E, Forno B, Lando G, Scarpati B, **Cairolì R**, Rossini S, Cesana C. Response of steroid-refractory chronic graft-versus-host disease to extracorporeal photopheresis correlates with the dose of CD3+ lymphocytes harvested during early treatment cycles. *Transfusion*. Feb;56(2):505-10. doi: 10.1111/trf.13369. Epub 2015 Oct 10. PMID: 26453579, 2016
- Carpenedo M, Cantoni S, Coccini V, Pogliani EM, **Cairolì R**. Response loss and development of neutralizing antibodies during long-term treatment with romiplostim in patients with immune thrombocytopenia: a case series. *Eur J Haematol*. Jul;97(1):101-103. doi: 10.1111/ejh.12733. Epub 2016 Feb 4. PMID: 26718013, 2016
- Frustaci AM, Rusconi C, Picardi P, Veronese S, Montillo M, **Cairolì R**, Tedeschi A. Bing Neel Syndrome in a Previously Untreated Patient With Waldenström's Macroglobulinemia: Contribution of MYD88 L265P Mutation on Cerebrospinal Fluid. *Clin Lymphoma Myeloma Leuk*. Jan;16(1):e7-9. doi: 10.1016/j.clml.2015.11.004. Epub 2015 Dec 2. PMID: 26705679, 2016
- Frustaci AM, Tedeschi A, Picardi P, **Cairolì R**, Montillo M. Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia. *Biologics*. Sep 18;9:75-86. doi: 10.2147/BTT.S60503. Review. PMID: 26425075, 2015
- Tedeschi A, Rossi D, Motta M, Quaresmini G, Rossi M, Coscia M, Anastasia A, Rossini F, Cortelezzi A, Nador G, Scarfò L, **Cairolì R**, Frustaci AM, Dalceglio D, Picardi P, De Paoli L, Orlandi E, Rambaldi A, Massaia M, Gaidano G, Montillo M. A phase II multi-center trial of pentostatin plus

cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients.; Rete Ematologica Lombarda–CLL Workgroup. *Haematologica*. 2015 Dec;100(12):e501-4. doi: 10.3324/haematol.2015.132035. Epub Aug 20. PMID: 26294723, 2015

- Mangiacavalli S, Pochintesta L, Ravelli E, Baldini L, Ferretti VV, La Targia ML, Farina L, Cocito F, **Cairolì R**, Montefusco V, Corso A. Panobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma, candidates for autologous transplant. *Leuk Lymphoma*. Jun;56(6):1901-2. doi: 10.3109/10428194.2014.979414. Epub 2015 Jan 14. PMID: 25347423, 2015

- Molteni A, Riva M, Cesana C, Speziale V, Nichelatti M, Scarpati B, Greco R, Ravano E, **Cairolì R**, Rossini S, Morra E. Prognostic relevance of the flow cytometric count of medullar blasts in myelodysplastic syndromes. *Eur J Haematol*. Jun;94(6):519-25. doi: 10.1111/ejh.12465. Epub 2014 Dec 4. PMID: 2530797, 2015

- Bertani G, Santoleri L, Martino M, Fedele R, Moscato T, Marengo P, Grillo G, Zucchetti E, Lotesoriere I, Lando G, Cesana C, **Cairolì R**, Rossini S. Identification of hematopoietic progenitor cell donor characteristics predicting successful mobilization: results of an Italian multicenter study. *Transfusion*. 2014 Aug;54(8):2028-33. doi: 10.1111/trf.12612. Epub 2014 Mar 3. PMID: 24588265, 2014

- Ricci F, Tedeschi A, Vismara E, Colombo C, Veronese S, Nichelatti M, **Cairolì R**, Morra E, Montillo M. Should a positive direct antiglobulin test be considered a prognostic predictor in chronic lymphocytic leukemia? *Clin Lymphoma Myeloma Leuk*. 2013 Aug;13(4):441-6. doi: 10.1016/j.clml.2013.02.024. Epub Jun 14. PMID: 23773451, 2013

- **Cairolì R**, Beghini A, Turrini M, Bertani G, Nadali G, Rodeghiero F, Castagnola C, Lazzaroni F, Nichelatti M, Ferrara F, Pizzolo G, Pogliani E, Rossi G, Martinelli G, Morra E. Old and new prognostic factors in acute myeloid leukemia with deranged core-binding factor beta. *Am J Hematol*, ISSN: 0361-8609, doi: 10.1002/ajh.23461, 2013

- Beghini A, Corlazzoli F, Del Giacco L, Re M, Lazzaroni F, Brioschi M, Valentini G, Ferrazzi F, Ghilardi A, Righi M, Turrini M, Mignardi M, Cesana C, Bronte V, Nilsson M, Morra E, **Cairolì R**. Regeneration-associated WNT signaling is activated in long-term reconstituting AC133bright acute myeloid leukemia cells. *Neoplasia*. Dec;14(12):1236-48. PMID: 23308055, 2012

- **Cairolì R**, Beghini A, Turrini M, Bertani G, Morra E. Prognostic markers in AML: focus on CBFL. *Leuk Suppl*. Aug;1(Suppl 2):S12-3. doi: 10.1038/leusup.2012.9. Epub 2012 Aug 9. PMID: 27175232, 2012

- Cristallo AF, Schroeder J, Citterio A, Santori G, Ferrioli GM, Rossi U, Bertani G, Cassano S, Gottardi P, Ceschini N, Barocci F, Ribizzi G, Cutrupi V, **Cairolì R**, Rapisarda V, Pastorello EA, Barocci S. A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis. *Int J Immunogenet*. Aug;38(4):303-9. doi: 10.1111/j.1744-313X.2011.01011.x. Epub 2011 May 4. PMID: 21545408, 2011

- Cesana C, Klersy C, Scarpati B, Brando B, Faleri M, Bertani G, Gatti A, Volpato E, Barba C, Ferri U, Scampini L, Grillo G, Lando G, Nosari A, Morra E, **Cairolì R**. Flow cytometry and cytomorphology evaluation of hematologic malignancy in cerebrospinal fluids: comparison with retrospective clinical outcome. *ANNALS OF HEMATOLOGY*, ISSN: 0939-5555, doi: 10.1007/s00277-010-1145-4, 2011

- Brioschi M, Fischer J, **Cairolì R.**, Rossetti S, Pezzetti L, Nichelatti M, Turrini M, Corlazzoli F, Scarpati B, Morra E, Sacchi N, Beghini A. Down-regulation of microRNAs 222/221 in acute

myelogenous leukemia with deranged core-binding factor subunits. *NEOPLASIA*, ISSN: 1522-8002, doi: 10.1593/neo.10482, 2010

- Cesana C, Klersy C, Scarpati B, Brando B, Volpato E, Bertani G, Faleri M, Nosari A, Cantoni S, Ferri U, Scampini L, Barba C, Lando G, Morra E, **Cairolì R**. Flow cytometry vs cytomorphology for the detection of hematologic malignancy in body cavity fluids. *Leuk Res.* Aug;34(8):1027-34. doi: 10.1016/j.leukres.2010.02.008. Epub 2010 Mar 5. PMID:20206995, 2010
- **Cairolì R**, Ripamonti CB, Beghini A, Granata S, Grillo G, Brioschi M, Nadali G, Viola A, Cattaneo C, Inropido L, Ravelli E, Bertani G, Pezzetti L, Nichelatti M, Marocchi A, Rossi G, Pizzolo G, Ferrara F, Nosari AM, Morra E. Total serum tryptase: a predictive marker for KIT mutation in acute myeloid leukemia. *LEUKEMIA RESEARCH*, ISSN: 0145-2126, doi: 10.1016/j.leukres.2009.03.043, 2009
- Trojani A, Ripamonti CB, Penco S, Beghini A, Nadali G, Di Bona E, Viola A, Castagnola C, Colapietro P, Grillo G, Pezzetti L, Ravelli E, Patrosso MC, Marocchi A, Cuneo A, Ferrara F, Lazzarino M, Pizzolo G, **Cairolì R**, Morra E. Molecular analysis of PDGFRA and PDGFRB genes by rapid single-strand conformation polymorphism (SSCP) in patients with core-binding factor leukaemias with KIT or FLT3 mutation. *Anticancer Res.* Sep-Oct;28(5A):2745-51. PMID: 19035305, 2008
- Cesana C, Klersy C, Brando B, Nosari A, Scarpati B, Scampini L, Molteni A, Nador G, Santoleri L, Formenti M, Valentini M, Mazzone A, Morra E, **Cairolì R**. Prognostic value of circulating CD34+ cells in myelodysplastic syndromes. *Leuk Res.* Nov;32(11):1715-23. doi: 10.1016/j.leukres.2008.03.028. Epub 2008 May 5. PMID: 18456323, 2008
- Arcaini L, Montanari F, Alessandrino EP, Tucci A, Brusamolino E, Gargantini L, **Cairolì R**, Bernasconi P, Passamonti F, Bonfichi M, Zoli V, Bottelli C, Calatroni S, Troletti D, Merli M, Pascutto C, Majolino I, Rossi G, Morra E, Lazzarino M. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. *Ann Oncol.* Jul;19(7):1331-5. doi: 10.1093/annonc/mdn044. Epub 2008 Mar 15. PMID: 18344536, 2008
- Corso A, Mangiacavalli S, Barbarano L, Alessandrino EP, **Cairolì R**, Morra E, Lazzarino M; HOST Group. Limited feasibility of double transplant in multiple myeloma: results of a multicenter study on 153 patients aged <65 years. *Cancer.* Jun 1;109(11):2273-8. PMID:17440982, 2007
- Nosari A, Ravini M, **Cairolì R**, Cozzi P, Marbello L, Marengo P, Grillo G, Morra E. Surgical resection of persistent pulmonary fungus nodules and secondary prophylaxis are effective in preventing fungal relapse in patients receiving chemotherapy or bone marrow transplantation for leukemia. *Bone Marrow Transplant.* May;39(10):631-5. Epub 2007 Mar 26. PMID: 17384656, 2007
- Nosari A, **Cairolì R**, Ciapanna D, Gargantini L, Intropido L, Baraté C, Scarpati B, Santoleri L, Nador G, Pezzetti L, Morra E. Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens. *Bone Marrow Transplant.* Sep;38(6):413-6. Epub 2006 Jul 31. PMID: 16878144, 2006
- Montillo M, Tedeschi A, Miqueleiz S, Veronese S, **Cairolì R**, Intropido L, Ricci F, Colosimo A, Scarpati B, Montagna M, Nichelatti M, Regazzi M, Morra E. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. *E. J Clin Oncol.* May 20;24(15):2337-42. Epub 2006 Apr 17. PMID: 16618945, 2006
- **Cairolì R**, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB, Colapietro P, Nichelatti M, Pezzetti L, Lunghi M, Cuneo A, Viola A, Ferrara F, Lazzarino M, Rodeghiero F, Pizzolo G, Larizza L, Morra E. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective

study.Blood. May 1;107(9):3463-8. Epub Dec 29. PMID:16384925, 2006

- Beghini A, Bellini M, Magnani I, Colapietro P, **Cairolì R**, Morra E, Larizza L. STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade. *Exp Hematol*. Jun;33(6):682-8. PMID: 1591109, 2005
- Perego RA, **Cairolì R**, Cornacchini G, Bianchi C, Corizzato M, Tresoldi E, Morra E. The role of quantitative polymerase chain reaction in the management of follicular lymphoma patients. *Tumori*. Jan-Feb;91(1):59-66. PMID: 15850006, 2005
- **Cairolì R**, Beghini A, Morello E, Grillo G, Montillo M, Larizza L, Morra E. Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases. *Leuk Res*. 2005 Apr;29(4):397-400. Epub Jan 12. PMID: 15725473, 2005
- Marbello L, Anghilieri M, Nosari A, Minola E, **Cairolì R**, Ricci F, Morra E. Aggressive systemic mastocytosis mimicking sclerosing cholangitis. *Haematologica*. ISSN: 1592-8721, 2004
- Corso A, Barbarano L, Zappasodi P, **Cairolì R**, Alessandrino EP, Mangiacavalli S, Ferrari D, Fava S, Fiumanò M, Frigerio G, Isa L, Luraschi A, Klersy C, De Paoli A, Vergani C, Banfi L, Perego D, Ucci G, Pinotti G, Savarè M, Uziel L, Vismara A, Morra E, Lazzarino M. The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma. *Haematologica*. Sep;89(9):1124-7. PMID: 15377474, 2004
- **Cairolì R**, Grillo G, Beghini A, Cornacchini G, Larizza L, Morra E. Chronic myelogenous leukemia with acquired c-kit activating mutation and transient bone marrow mastocytosis. *E. Hematol J* ; 5(3):273-5. PMID: 15167915, 2004
- **Cairolì R**, Grillo G, Tedeschi A, D'Avanzo G, Marenco P, Morra E. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. *Haematologica*. Mar;89(3):361-3. PMID: 15020279, 2004
- Beghini A, Ripamonti CB, **Cairolì R.**, Cazzaniga G, Colapietro P, Elice F, Nadali G, Grillo G, Haas OA, Biondi A, Morra E, Larizza L. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. *HAEMATOLOGICA*. ISSN: 0390-6078, 2004
- Montillo M, Tedeschi A, Rossi V, **Cairolì R.**, Pungolino E, Intropido L, Cafro AM, D'Avanzo G, Farioli R, Brando B, Scarpati B, Veronese S, Morra E. Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H. *LEUKEMIA*. ISSN: 0887-6924, doi: 10.1038/sj.leu.2403190, 2004
- **Cairolì R**, Grillo G, Beghini A, Tedeschi A, Ripamonti CB, Larizza L, Morra E. C-Kit point mutations in core binding factor leukemias: correlation with white blood cell count and the white blood cell index. *LEUKEMIA*. ISSN: 0887-6924, doi: 10.1038/sj.leu.2402795, 2003
- Molecular remission and reconstitution of a full chimera with arsenic trioxide in a patient with acute promyelocytic leukemia relapsed after allogeneic bone marrow transplantation. *Tedeschi A, Cairolì R, Marenco P, Nosari A, Tresoldi E, Di Bona E, Montillo M, Morra E. Leukemia*. Dec;16(12):2455-6. PMID: 12454753, 2002

- Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Montillo M, Cafro AM, Tedeschi A, Brando B, Oreste P, Veronese S, Rossi V, **Cairolì R**, Pungolino E, Morra E. Haematologica. Jul;87(7):695-700. PMID: 12091119, 2002
- Effective treatment of autoimmune hemolytic anemia and hairy cell leukemia with interferon-alpha. Cesana C, Brando B, Boiani E, Chiodo F, **Cairolì R**, Intropido L, Morra E. Eur J Haematol. Feb;68(2):120-1. PMID: 1198261, 2002
- Tedeschi A, Montillo M, **Cairolì R**, Marengo P, Cafro A, Oreste P, Nosari A, Morra E. Prior invasive pulmonary and cerebellar mucormycosis is not a primary contraindication to perform an autologous stem cell transplantation in leukemia. LEUKEMIA & LYMPHOMA. ISSN: 1042-8194, doi: 10.1080/10428190290012236, 2002
- Lazzarino M, Arcaini L, Bernasconi P, Alessandrino EP, Gargantini L, **Cairolì R**, Orlandi E, Astori C, Brusamolino E, Pagnucco G, Colombo AA, Calatroni S, Iacona I, Regazzi MB, Morra E. A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. BRITISH JOURNAL OF HAEMATOLOGY. ISSN: 0007-1048, doi: 10.1046/j.1365-2141.2002.03256.x, 2002
- **Cairolì R**, Grillo G, Tedeschi A, Gargantini L, Marengo P, Tresoldi E, Barbarano L, Nosari AM, Morra E. Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis. BONE MARROW TRANSPLANTATION. ISSN: 0268-3369, doi: 10.1038/sj/bmt/1703401, 2002
- Montillo M, Cafro AM, Tedeschi A, Brando B, Oreste P, Veronese S, Rossi V, **Cairolì R**, Pungolino E, Morra E. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. HAEMATOLOGICA. ISSN: 0390-6078, 2002
- Cesana C, Brando B, Boiani E, Chiodo F, **Cairolì R**, Intropido L, Morra E. Effective treatment of autoimmune hemolytic anemia and hairy cell leukemia with interferon-alpha. EUROPEAN JOURNAL OF HAEMATOLOGY, ISSN: 0902-4441, 2002
- Lazzarino M, Corso A, Barbarano L, Alessandrino EP, **Cairolì R**, Pinotti G, Ucci G, Uziel L, Rodeghiero F, Fava S, Ferrari D, Fiumanò M, Frigerio G, Isa L, Luraschi A, Montanara S, Morandi S, Perego D, Santagostino A, Savarè M, Vismara A, Morra E. DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. BONE MARROW TRANSPLANTATION, ISSN: 0268-3369, doi: 10.1038/sj.bmt.1703240, 2001
- Invasive aspergillosis in haematological malignancies: clinical findings and management for intensive chemotherapy completion. Nosari A, Oreste P, **Cairolì R**, Montillo M, Carrafiello G, Astolfi A, Muti G, Marbello L, Tedeschi A, Magliano E, Morra E. Am J Hematol. Dec 68(4):231-6. PMID: 11754411, 2001
- Beghini A, Peterlongo P, Ripamonti CB, Larizza L, **Cairolì R**, Morra E, Mecucci C. C-kit mutations in core binding factor leukemias. BLOOD, ISSN: 0006-4971, 2000
- Beghini A, Ripamonti CB, Castorina P, Pezzetti L, Doneda L, **Cairolì R**, Morra E, Larizza L. Trisomy 4 leading to duplication of a mutated KIT allele in acute myeloid leukemia with mast cell

involvement. CANCER GENETICS AND CYTOGENETICS, ISSN: 0165-4608, doi: 10.1016/S0165-4608(99)00221-6, 2000

- Beghini A, Ripamonti CB, Peterlongo P, Roversi G, **Cairolì R**, Morra E, Larizza L. RNA hyperediting and alternative splicing of hematopoietic cell phosphatase (PTPN6) gene in acute myeloid leukemia. HUMAN MOLECULAR GENETICS. ISSN: 0964-6906, 2000

- c-kit activating mutations and mast cell proliferation in human leukemia. Beghini A, Larizza L, **Cairolì R**, Morra E. Blood ; 92 (2):701-702, 1998

- Beghini A, **Cairolì R**, Morra E, Larizza L. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation. BLOOD CELLS, MOLECULES, & DISEASES, ISSN: 1079-9796, doi: 10.1006/bcmd.1998.0191, 1998

- Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. For AO Niguarda, **Cairolì R**. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. BRITISH JOURNAL OF HAEMATOLOGY. ISSN: 0007-1048, 1998

- **Cairolì R**, Crugnola M, Morra E. Complications at insertion of untunnelled central venous catheters (UCVCs) in leukemic patients at a high risk of hemorrhage. HAEMATOLOGICA, ISSN: 0390-6078, 1997

- Perego RA, Marengo P, Bianchi C, **Cairolì R**, Urbano M, Nosari AM, Muti G, Morra E, Del Monte U. PML/RAR alpha transcripts monitored by polymerase chain reaction in acute promyelocytic leukemia during complete remission, relapse and after bone marrow transplantation. LEUKEMIA, vol. 10; p. 207-212, ISSN: 0887-6924, 1996

- **Cairolì R.**, Marengo P, Perego R, de Cataldo F. Saccharomyces cerevisiae fungemia with granulomas in the bone marrow in a patient undergoing BMT. BONE MARROW TRANSPLANTATION, ISSN: 0268-3369, 1995

- de Cataldo F, **Cairolì R**, Baudo F, Pezzetti L, Lo Cunsolo CL, Perutelli P, Mori PG. Abnormalities of cytoskeletal proteins of the red blood cells in myelodysplastic syndromes. INTERNATIONAL JOURNAL OF HEMATOLOGY, ISSN: 0925-5710 , 1994

- Nosari A, Cantoni S, Muti G, **Cairolì R**, Cipriani D, de Cataldo F. Itraconazole in leukemic patients with invasive aspergillosis (IA): impact on intensive chemotherapy completion. EUROPEAN JOURNAL OF HAEMATOLOGY, ISSN: 0902-4441, 1994

- **Cairolì R**, De Gasperi A, Gimmelli A, Nosari A, De Cataldo F. Untunnelled central venous catheters in the treatment of acute leukemia. HAEMATOLOGICA, ISSN: 0390-6078, 1993

STUDI COOPERATIVI INTERNAZIONALI (Con apporto casistico riconosciuto nella pubblicazione):

- Treatment of aplastic anaemia (AA) with antilymphocyte globulin (ALG) and methylprednisolone (MPred) with or without androgens: a randomized trial from the EBMT SAA working party. British J Haematol 83: 145-151, 1993.
- Impact of liver disease and hepatitis infections on allogeneic bone marrow transplantation in Europe: a survey from the European Bone Marrow Transplantation (EBMT) Group-Infectious diseases Working Party. Bone Marrow Transplantation 14: 833-837, 1994.

- Indications and source of hematopoietic stem cell transplant in Europe 1993. Report from the European Group for Blood and Marrow Transplantation (EBMT). *Clin Transplantation* 9:355-363, 1995.
- Blood and marrow transplantation activity in Europe 1995. For the European Group for Blood and Marrow Transplantation (EBMT). *Bone Marrow Transplantation* 19: 407-419, 1997.
- A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. For Italian Cooperative Study Group for rHuEpo in myelodysplastic syndromes. *British J Haematol* 103: 1070-74, 1998.
- Hematopoietic precursor cell transplants in Europe: activity in 1994. Report from EBMT. A. Gratwohl, J Hermans, H Baldomero. *Bone Marrow Transplantation* 17 : 137-148,1996.
- Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. A. Gratwohl, J Hermans, JM Goldman et al. *Lancet* 352 : 1087-1092,1998.
- Blood and Marrow transplantation activity in Europe 1997. A. Gratwohl, J Passweg, H Baldomero , J Hermans for EBMT. *Bone Marrow Transplantation* 24 : 231-245,1999.
- Reduction of intra- and interlaboratory variation in CD34+ stem cell enumeration using stable test material, standard protocols and targeted training. *British J Haematol* 108: 784-792, 2000.
- Hematopoietic stem cell transplantation activity in Europe 1999. A. Gratwohl, J Passweg, H Baldomero , A Urbano-Ispizua for EBMT. *Bone Marrow Transplantation* 27 : 899-916, 2001.
- Current trends in Hematopoietic stem cell transplantation in Europe. A. Gratwohl, H Baldomero et al for EBMT. *Blood* 100: 2374-2386, 2002.
- Hematopoietic stem cell transplantation for hematological malignancies in Europe. A. Gratwohl, H. Baldomero, J. Passweg , F. Frassoni, D. Niederwieser, N. Schmitz, A Urbano-Ispizua for EBMT. *Leukemia* 17:941-959, 2003.
- Evolution of Haematopoietic stem cell transplantation in Eastern and Western Europe from 1990 to 2003. A report from the EBMT activity survey. A. Gratwohl, H. Baldomero, B. Labar, J. Apperley, A Urbano-Ispizua for the Accreditation Committee of the EBMT. *Croatia Medical Journal*. 45: 689-694, 2004.
- Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy. A report from the EBMT Chronic Malignancies Working Party. Koenecke C et al. *Bone Marrow Transplantation* 51(9):1259-61, 2016.
- Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation. Van Gelder M et al. *Bone Marrow Transplantation*. (52) 3;372-380, 2017.

